PSY (Defiance Next Gen Altered Experience ETF) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.

See exactly how PSY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PSY and 80,000+ other tickers.
This fund is designed to mirror a systematically constructed index. This index evaluates the performance of companies engaged in specific, legally authorized activities, always in adherence to national laws. These activities encompass the fields of medical psychedelics, therapeutic cannabis, cannabis-derived pharmaceuticals, cannabidiol (CBD) derivatives, and ketamine. To achieve its financial goals, the fund utilizes a full replication approach, meaning it directly invests in all the constituent securities of the underlying index, striving to maintain their proportional weightings. It functions as a non-diversified investment product.

On July 13, 2022, two amendments passed in the House of Representatives that would provide psychedelic drug treatment to veterans and active duty service members. A documentary based on Michael Pollan's 2018 book, "How to Change Your Mind," is one of Netflix's most-watched shows.

A new thematic ETF providing exposure to the medicinal psychedelic drug industry, PSYK ETF, has just been launched.

Psychedelic substances are often grouped together with cannabis, but there are some important distinctions. ATAI, CMPS and FTRP are some of the best stocks in the space.

No matter what comes next, there will be an ETF for it.

Psychedelic drugs can be used to treat a range of mental health and neurological issues.